Ixabepilone
Ixabepilone (Ixempra) is a chemotherapy infusion for breast cancer that has stopped responding to anthracyclines, taxanes and capecitabine.
Overview
Ixabepilone, a semi-synthetic epothilone, was approved by the FDA in October 2007 with capecitabine for metastatic or locally advanced breast cancer resistant to an anthracycline and a taxane (a 752-patient randomised trial showed longer progression-free survival than capecitabine alone) and as monotherapy after anthracycline, taxane and capecitabine failure. The EMA refused a marketing authorisation in 2008 on the balance of benefit and toxicity. Peripheral neuropathy is dose-limiting; the combination is contraindicated with hepatic impairment because of excess toxic deaths, and the Cremophor-based diluent requires premedication for hypersensitivity.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas: how tumours escape and what closes the route · Lines of therapy.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2007 | Metastatic or locally advanced breast cancer after anthracycline and taxane (with capecitabine) or after anthracycline, taxane and capecitabine (monotherapy) |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Ixabepilone" OR ABSTRACT:"Ixabepilone" OR TITLE:"Ixempra" OR ABSTRACT:"Ixempra") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ixabepilone, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductClofarabine
Shares Cytotoxic chemotherapy and the tag nci-list.
- ProductThiotepa
Shares Cytotoxic chemotherapy, HR-positive / HER2-negative breast cancer and the tag nci-list.
- ProductNelarabine
Shares Cytotoxic chemotherapy and the tag nci-list.
- ProductBusulfan
Shares Cytotoxic chemotherapy and the tag nci-list.
- ProductProcarbazine
Shares Cytotoxic chemotherapy and the tag nci-list.
- ProductToremifene
Shares HR-positive / HER2-negative breast cancer and the tag nci-list.
- ProductTriptorelin
Shares HR-positive / HER2-negative breast cancer and the tag nci-list.
- ProductEpirubicin
Shares Cytotoxic chemotherapy, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag nci-list.